Royce & Associates’s Profound Medical PROF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.55M | Buy |
764,906
+3,107
| +0.4% | +$18.5K | 0.05% | 478 |
|
|
2025
Q1 | $4.35M | Sell |
761,799
-3,000
| -0.4% | -$17.1K | 0.05% | 469 |
|
|
2024
Q4 | $5.75M | Buy |
764,799
+195,501
| +34% | +$1.47M | 0.05% | 453 |
|
|
2024
Q3 | $4.53M | Buy |
569,298
+3,500
| +0.6% | +$27.8K | 0.04% | 495 |
|
|
2024
Q2 | $4.85M | Buy |
565,798
+1,500
| +0.3% | +$12.9K | 0.05% | 487 |
|
|
2024
Q1 | $4.76M | Hold |
564,298
| – | – | 0.04% | 500 |
|
|
2023
Q4 | $4.73M | Sell |
564,298
-5,600
| -1% | -$46.9K | 0.04% | 501 |
|
|
2023
Q3 | $5.71M | Buy |
569,898
+3,900
| +0.7% | +$39.1K | 0.06% | 452 |
|
|
2023
Q2 | $7.25M | Sell |
565,998
-5,100
| -0.9% | -$65.3K | 0.07% | 408 |
|
|
2023
Q1 | $5.29M | Buy |
571,098
+22,900
| +4% | +$212K | 0.05% | 470 |
|
|
2022
Q4 | $5.86M | Buy |
548,198
+103,300
| +23% | +$1.1M | 0.06% | 417 |
|
|
2022
Q3 | $1.8M | Sell |
444,898
-58,000
| -12% | -$235K | 0.02% | 644 |
|
|
2022
Q2 | $3.67M | Sell |
502,898
-2,100
| -0.4% | -$15.3K | 0.04% | 558 |
|
|
2022
Q1 | $4.54M | Sell |
504,998
-61,500
| -11% | -$553K | 0.04% | 569 |
|
|
2021
Q4 | $6.39M | Buy |
566,498
+48,898
| +9% | +$551K | 0.05% | 504 |
|
|
2021
Q3 | $7.56M | Buy |
517,600
+41,000
| +9% | +$599K | 0.06% | 486 |
|
|
2021
Q2 | $7.76M | Buy |
476,600
+18,200
| +4% | +$296K | 0.05% | 496 |
|
|
2021
Q1 | $9.19M | Buy |
458,400
+157,400
| +52% | +$3.16M | 0.06% | 469 |
|
|
2020
Q4 | $6.19M | Buy |
301,000
+291,000
| +2,910% | +$5.99M | 0.05% | 505 |
|
|
2020
Q3 | $176K | Sell |
10,000
-283,000
| -97% | -$4.98M | ﹤0.01% | 943 |
|
|
2020
Q2 | $4.96M | Hold |
293,000
| – | – | 0.05% | 462 |
|
|
2020
Q1 | $2.82M | Buy |
293,000
+98,000
| +50% | +$943K | 0.04% | 515 |
|
|
2019
Q4 | $2.22M | Buy |
+195,000
| New | +$2.22M | 0.02% | 681 |
|